Human Mesenchymal Stem Cells For Bronchopulmonary Dysplasia
Status:
Recruiting
Trial end date:
2022-06-30
Target enrollment:
Participant gender:
Summary
This study is an open-label, single-center, dose escalation study to evaluate of safety and
efficacy of human umbilical cord -derived mesenchymal stem cells (hUC-MSCs) in premature
infants for moderate and severe Bronchopulmonary Dysplasia（BPD）.
Phase:
Phase 1
Details
Lead Sponsor:
Children's Hospital of Chongqing Medical University